Changes in serum prolactin level during intracytoplasmic sperm injection, and effect on clinical pregnancy rate: a prospective observational study

Ahmed Kamel, Ayman A Halim, Mohamed Shehata, Salwa AlFarra, Yahia El-Faissal, Wafaa Ramadan, Ahmed M Hussein, Ahmed Kamel, Ayman A Halim, Mohamed Shehata, Salwa AlFarra, Yahia El-Faissal, Wafaa Ramadan, Ahmed M Hussein

Abstract

Background: Transient hyperprolactinemia was proven to adversely affect the outcome of IVF. We aimed to identify changes in serum prolactin levels in patients undergoing ICSI, and to evaluate the effect of these changes on the clinical pregnancy rate.

Methods: A prospective observational study included 90 patients scheduled for ICSI cycles. In each case 4 serum samples were collected during the cycle (midluteal, before ovum pick up procedure (OPU), 2 h after OPU, and before embryo transfer). Serum prolactin level was determined by immunoassay each time.

Results: The sample collected 2 h after OPU had a mean difference of 25.8 ± 2.8 ng/ml compared to the basal serum prolactin (p < 0.01). In comparison to other samples, this highlighted a significant hyperprolactinemia occurring after OPU, and resolving before embryo transfer. No statistically significant difference between the different serum prolactin samples amongst the pregnant and non pregnant patients. There was a significant positive pearson correlation between the prolactin levels before OPU, and the presence of higher quality embryos (r = 0.274, p = 0.019).

Conclusion: In normoprolactinemic women transient hyperprolactinemia is identified in patients undergoing ICSI, and it doesn't affect the clinical pregnancy rates. A positive correlation was identified between higher quality embryos, and serum prolactin level before OPU.

Trial registration: ClinicalTrials.gov Identifier: NCT02292953 , First received: November 10, 2014.

Keywords: Embryo quality; Hyperprolactinemia; Intracytoplasmic sperm injection; Prolactin.

Conflict of interest statement

Authors’ information

All authors of this work have years of experience in the field of ART.

Ethics approval and consent to participate

The Scientific & Ethics committee of Cairo University’s OBGYN department approved this study, and permission to the conduct the study was granted by the assisted conception unit of Kasr Alainy hospital. All participants in the study signed a written informed consent.

Competing interests

The authors of this study declare no conflict of interest and no competing interests with respect to the research, authorship, and publication of this article.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Scatter plot showing correlation between serum prolactin levels before OPU and high quality embryos

References

    1. Majumdar A, Mangal NS. Hyperprolactinemia. J Hum Reprod Sci. 2013;6(3):168–175. doi: 10.4103/0974-1208.121400.
    1. Chawla R, Antonios T, Berhanu E, Ayana G. Journal of medical biochemistry. 2012. Detection of Macroprolactinemia and molecular characterization of prolactin isoforms in blood samples of hyperprolactinemic women; p. 19.
    1. Y-p Z, Shen X-t, Ying Y, Wu H-T, Li J, Qi Q, Zhou C-Q, Zhuang G-L. Journal of medical biochemistry. 2012. Impact of transitory hyperprolactinemia on clinical outcome of in vitro fertilization and embryo transfer; p. 27.
    1. Boyers SP, Lavy G, Russell JB, Polan ML, DeCherney AH. Serum prolactin response to embryo transfer during human in vitro fertilization and embryo transfer. J In Vitro Fert Embryo Transf. 1987;4(5):269–272. doi: 10.1007/BF01555202.
    1. Huang KE, Bonfiglio TA, Muechler EK. Transient hyperprolactinemia in infertile women with luteal phase deficiency. Obstet Gynecol. 1991;78(4):651–655.
    1. Reinthaller A, Deutinger J, Csaicsich P, Riss P, Muller-Tyl E, Fischl F, Janisch H. Effect of serum prolactin on cycle stimulation and fertilization of human oocytes. Geburtshilfe Frauenheilkd. 1987;47(4):246–248. doi: 10.1055/s-2008-1035816.
    1. del Pozo E. Management of borderline hyperprolactinemia. Horm Res. 1985;22(3):204–208. doi: 10.1159/000180095.
    1. Chang SP, Ng HT, Lan TL, Chao HT, Wei TC, Yang TS, Ou-Yang XR. Transient hyperprolactinemia in gonadotropin-stimulated cycles for in vitro fertilization and its effect on conception. Zhonghua Yi Xue Za Zhi. 1993;51(6):401–406.
    1. Pattinson HA, Taylor PJ, Fleetham JA, Servis SA. Transient hyperprolactinemia has no effect on endocrine response and outcome in in vitro fertilization (IVF) J In Vitro Fert Embryo Trans. 1990;7(2):89–93. doi: 10.1007/BF01135580.
    1. Hummel WP, Clark MR, Talbert LM. Transient hyperprolactinemia during cycle stimulation and its influence on oocyte retrieval and fertilization rates. Fertil Steril. 1990;53(4):677–681. doi: 10.1016/S0015-0282(16)53463-3.
    1. Mendoza C, Cremades N, Ruiz-Requena E, Martinez F, Ortega E, Bernabeu S, Tesarik J. Relationship between fertilization results after intracytoplasmic sperm injection, and intrafollicular steroid, pituitary hormone and cytokine concentrations. Hum Reprod. 1999;14(3):628–635. doi: 10.1093/humrep/14.3.628.
    1. Jinno M, Katsumata Y, Hoshiai T, Nakamura Y, Matsumoto K, Yoshimura Y. A therapeutic role of prolactin supplementation in ovarian stimulation for in vitro fertilization: the bromocriptine-rebound method. J Clin Endocrinol Metab. 1997;82(11):3603–3611. doi: 10.1210/jcem.82.11.4349.
    1. Jinno M, Yoshimura Y, Ubukata Y, Nakamura Y. A novel method of ovarian stimulation for in vitro fertilization: bromocriptine-rebound method. Fertil Steril. 1996;66(2):271–274. doi: 10.1016/S0015-0282(16)58452-0.
    1. Kamel MA, Zabel G, Bernart W, Neulen J, Breckwoldt M. Comparison between prolactin, gonadotrophins and steroid hormones in serum and follicular fluid after stimulation with gonadotrophin-releasing hormone agonists and human menopausal gonadotrophin for an in-vitro fertilization programme. Hum Reprod. 1994;9(10):1803–1806. doi: 10.1093/oxfordjournals.humrep.a138338.
    1. Raosoft Sample size calculator. . Accessed 3 May 2018.
    1. Mansour R, Fahmy I, Tawab NA, Kamal A, El-Demery Y, Aboulghar M, Serour G. Electrical activation of oocytes after intracytoplasmic sperm injection: a controlled randomized study. Fertil Steril. 2009;91(1):133–139. doi: 10.1016/j.fertnstert.2007.08.017.
    1. Rockliff HE, Lightman SL, Rhidian E, Buchanan H, Gordon U, Vedhara K. A systematic review of psychosocial factors associated with emotional adjustment in in vitro fertilization patients. Hum Reprod Update. 2014;20(4):594–613. doi: 10.1093/humupd/dmu010.
    1. Li XH, Ma YG, Geng LH, Qin L, Hu H, Li SW. Baseline psychological stress and ovarian norepinephrine levels negatively affect the outcome of in vitro fertilisation. Gynecol Endocrinol. 2011;27(3):139–143. doi: 10.3109/09513590.2010.501871.
    1. Turner K, Reynolds-May MF, Zitek EM, Tisdale RL, Carlisle AB, Westphal LM. Stress and anxiety scores in first and repeat IVF cycles: a pilot study. PLoS One. 2013;8(5):e63743. doi: 10.1371/journal.pone.0063743.
    1. Nouri K, Litschauer B, Huber JC, Buerkle B, Tiringer D, Tempfer CB. Saliva cortisol levels and subjective stress are not associated with number of oocytes after controlled ovarian hyperstimulation in patients undergoing in vitro fertilization. Fertil Steril. 2011;96(1):69–72. doi: 10.1016/j.fertnstert.2011.04.063.
    1. Doldi N, Papaleo E, De Santis L, Ferrari A. Treatment versus no treatment of transient hyperprolactinemia in patients undergoing intracytoplasmic sperm injection programs. Gynecol Endocrinol. 2000;14(6):437–441. doi: 10.3109/09513590009167716.
    1. Lebedeva IY, Singina GN, Lopukhov AV, Shedova EN, Zinovieva NA. Prolactin and growth hormone affect metaphase-II chromosomes in aging oocytes via cumulus cells using similar signaling pathways. Front Genet. 2015;6:274. doi: 10.3389/fgene.2015.00274.
    1. Gonen Y, Casper RF. Does transient hyperprolactinemia during ovarian hyperstimulation interfere with conception or pregnancy outcome? Fertil Steril. 1989;51(6):1007–1010. doi: 10.1016/S0015-0282(16)60734-3.
    1. Jinno M, Ubukata Y, Satou M, Katsumata Y, Yoshimura Y, Nakamura Y. A novel method of ovarian stimulation for in vitro fertilization (bromocriptine-rebound method) increases developmental potential of oocytes and pregnancy rate. Nihon Sanka Fujinka Gakkai zasshi. 1995;47(12):1337–1344.
    1. Moride N, Kuwahara A, Yamashita M, Tanaka Y, Matsuzaki T, Yasui T, Irahara M. Does the bromocriptine-rebound method improve embryo quality? J Med Invest. 2011;58(1–2):63–66. doi: 10.2152/jmi.58.63.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever